Bio-Techne (TECH) awards give executive 5,423 shares, 1,947 withheld
Rhea-AI Filing Summary
BIO-TECHNE Corp (TECH) reported insider equity activity by executive Steven C. Crouse, President - Diag & Spatial Bi. On 2026-08-15, Crouse exercised or converted restricted stock units into 5,423 shares of common stock, with no exercise price shown.
In connection with this, 1,947 common shares were disposed of at $72.40 per share for payment of exercise price or tax liability by delivering or withholding securities. Several equity awards and stock options remain outstanding, including multiple option grants with exercise prices between the mid-$40s and low-$120s and expirations from 2028 through 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 3,476 shares
Net Buy
18 txns
Insider
Crouse Steven C.
Role
President - Diag & Spatial Bi
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F1, F4 | 1,379 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F1, F5 | 1,868 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F1, F6 | 2,176 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,423 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 1,947 | $72.40 | $141K |
| holding | Restricted Stock Units F1, F2 | -- | -- | -- |
| holding | Restricted Stock Units F1, F3 | -- | -- | -- |
| holding | Stock Option (right to buy) F7 | -- | -- | -- |
| holding | Stock Option (right to buy) F7 | -- | -- | -- |
| holding | Stock Option (right to buy) F8 | -- | -- | -- |
| holding | Stock Option (right to buy) F9 | -- | -- | -- |
| holding | Stock Option (right to buy) F10 | -- | -- | -- |
| holding | Stock Option (right to buy) F11 | -- | -- | -- |
| holding | Stock Option (right to buy) F12 | -- | -- | -- |
| holding | Stock Option (right to buy) F13 | -- | -- | -- |
| holding | Performance Restricted Stock Units F1, F14 | -- | -- | -- |
| holding | Restricted Stock Units F1, F15 | -- | -- | -- |
| holding | Stock Option (right to buy) F16 | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 8,951 shares (Direct);
Common Stock — 10,237 shares (Direct);
Stock Option (right to buy) — 111,053 shares (Direct);
Performance Restricted Stock Units — 2,387 shares (Direct)
Footnotes (16)
- F1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F2. 794 restricted stock units vest on 5/1/2027.
- F3. 600 restricted stock units vest on each of 6/2/2027 and 6/2/2028.
- F4. 1,379 restricted stock units vest on 8/15/2026.
- F5. 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027.
- F6. 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027.
- F7. 100% vested.
- F8. Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
- F9. Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.
- F10. Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.
- F11. Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.
- F12. Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.
- F13. Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.
- F14. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F15. 245 restricted stock units vest on 3/2/2027, 3/2/2028 and 3/2/2029.
- F16. Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029.
Key Figures
Common shares acquired via RSU conversion: 5,423 shares
Shares delivered/withheld for exercise price or tax liability: 1,947 shares
Disposition price: $72.40 per share
+5 more
8 metrics
Common shares acquired via RSU conversion
5,423 shares
Shares of BIO-TECHNE common stock received on 2026-08-15 from restricted stock units
Shares delivered/withheld for exercise price or tax liability
1,947 shares
Common shares disposed of at $72.40 per share on 2026-08-15
Disposition price
$72.40 per share
Price for 1,947 common shares delivered or withheld for exercise price or tax liability
Stock options outstanding at $120.46
19,032 underlying shares
Stock options with $120.4600 exercise price expiring 2028-08-06
Stock options outstanding at $94.52
24,560 underlying shares
Stock options with $94.5200 exercise price expiring 2029-08-15
Performance RSUs held
2,387 units
Performance Restricted Stock Units tied to 2,387 underlying common shares
RSUs vesting on 2026-08-15 (F4)
1,379 units
Restricted stock units scheduled to vest on 2026-08-15 per vesting footnote
RSUs vesting across 2026-2028 (F6, first tranche)
2,176 units
One of several 2,176-unit tranches vesting on 2026-08-15 and 2028-08-15
Key Terms
Restricted Stock Units, Performance Restricted Stock Units, Stock Option (right to buy), exercise price, +1 more
5 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Restricted Stock Units financial
"Vests in full or in part on 8/15/2028 if certain performance goals"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Stock Option (right to buy) financial
"Stock Option (right to buy) underlying common stock with specified exercise price"
exercise price financial
"Stock options list an exercise price such as 120.4600 or 94.5200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Payment of exercise price or tax liability by delivering or withholding securities financial
"Code F transaction description notes payment of exercise price or tax liability"
FAQ
What insider transaction did TECH executive Steven C. Crouse report?
Steven C. Crouse reported exercising or converting equity awards into 5,423 shares of BIO-TECHNE common stock on 2026-08-15. This arose from restricted stock units converting into common shares as part of his compensation-related equity awards.
What derivative equity awards does Steven C. Crouse still hold in TECH?
Crouse continues to hold several derivative awards, including stock options over 19,032 shares at $120.46 expiring 2028-08-06 and options over 24,560 shares at $94.52 expiring 2029-08-15, along with additional options and restricted stock units shown in the filing.
Were Steven C. Crouse’s TECH transactions under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and there is no footnote stating that the transactions were made pursuant to a Rule 10b5-1 or other pre-arranged trading plan.
What performance-based equity does Steven C. Crouse hold in BIO-TECHNE (TECH)?
Crouse holds 2,387 Performance Restricted Stock Units, each tied to one share of common stock. These units vest in full or in part on 2028-08-15, subject to achieving certain performance goals and subsequent certification.
AI-generated analysis. How Rhea-AI works. Not financial advice.
